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The main aim of this systematic review was to analyse and compare the clinical effi-
cacy and safety of metronidazole, vancomycin and fidaxomicin in the therapy of C. 
difficile infection. Methods: Systematic review and meta-analysis of the literature 
using Bayesian mixed treatment comparison. Results: Nine studies were included 
in the mixed-treatment comparison. Our meta-analysis showed that clinical cure 
was more likely with fidaxomicin compared to vancomycin and metronidazole, 
however the differences were not significant. (odds ratios [95% CI]: fidaxomicin 
vs. vancomycin 1.19 [0.82-1.66]; vancomycin vs. metronidazole 1.69 [0.93-2.82] and 
fidaxomicin vs. metronidazole 2.00 [0.99-3.66]). Fidaxomicin therapy was signifi-
cantly more efficacious than vancomycin and metronidazole in endpoints of recur-
rence (odds ratios [95% CI]: fidaxomicin vs. vancomycin 0.47 [0.33-0.65]; vancomycin 
vs. metronidazole 0.91 [0.44-1.69] and fidaxomicin vs. metronidazole 0.43 [0.19-0.85]) 
and sustained cure (odds ratios [95% CI]: fidaxomicin vs. vancomycin 1.77 [1.35-
2.28]; vancomycin vs. metronidazole 1.49 [0.92-2.30]; and fidaxomicin vs. metroni-
dazole 2.64 [1.50-4.35]. There was no significant difference between fidaxomicin, 
vancomycin and metronidazole in safety endpoints. ConClusions: Fidaxomicin 
was the most efficacious therapeutic alternative in lowering the rate of recurrent 
C. difficile infections.
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objeCtives: To conduct mixed treatment comparisons (MTC) to compare sime-
previr, a new generation NS3/4A protease inhibitor, with boceprevir and telaprevir 
(all in combination with PR) and with PR alone in treatment-naïve and treatment-
experienced genotype 1 HCV infected patients. These MTC results were used to 
inform the cost-effectiveness model for simeprevir and to prepare submissions to 
HTA agencies (including NICE). Methods: A Bayesian MTC based on a systematic 
literature review was conducted. Outcomes of interest included sustained virologic 
response (SVR) rates, incidence of anaemia and rash and discontinuation due to 
adverse events (AEs) rates. Networks were based on treatment-, dose- and duration-
specific nodes. Q80K-positive patients were excluded from simeprevir arms for the 
analysis of SVR rates in line with EMA label considerations for simeprevir. Subgroup 
analyses were conducted to investigate heterogeneity, based on METAVIR scores, 
sub-genotypes 1a/1b and prior response. Results: Simeprevir was associated with 
higher SVR rates than PR alone in both treatment-naive (OR [95%CrI]: 4.83 [3.50-
6.70]) and treatment-experienced patients (ORs: 9.02 [5.54-15.01]) for simeprevir 
12+PR 24/48 weeks and 8.73 [5.42-14.19] for simeprevir 12 +PR 48 weeks). Compared 
to telaprevir and boceprevir, SVR rates tended to be higher for simeprevir with 
odds-ratios ranging from 1.27 [0.81-2.00] to 2.61 [1.44-4.74] in treatment-naïve and 
from 1.04 [0.78-1.38] to 1.74 [0.84-3.61] in treatment-experienced patients. In terms 
of safety, the risks of anaemia and discontinuations due to AEs were lower for 
simeprevir compared to PR alone, telaprevir and boceprevir. The risk of rash was 
lower for simeprevir compared to telaprevir, and similar compared to PR alone and 
boceprevir. ConClusions: This MTC in genotype 1 HCV patients suggests a similar 
or better efficacy and a better tolerability profile for simeprevir compared to tel-
aprevir and boceprevir both in treatment-naïve and treatment-experienced patients.
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objeCtives: Widespread uncontrolled use of antibiotics contributes to the develop-
ment of microbial resistance. Study of antibiotic consumption by ATC / DDD method 
in terms of DDDs/1000 inhabitants / day (DID) is one of the ways to control the 
resistance development rate. Macrolide antibiotics are widely used for treatment 
of infectious diseases; therefore, their consumption needs control. Methods: Data 
on packed macrolides consumption in Ukraine, Russia and Kazakhstan, provided 
by analytical companies researching pharmaceutical market - “Pharmstandard” 
and IMS Health, has been used for the study. Results: Comparing the figures in 
Ukraine, Russia and Kazakhstan, the largest consumption (in DID) was observed in 
Russia, Ukraine was in the second place, Kazakhstan was in the third place, during 
2010-2012. However, the data were not significantly different; indices were 1.496, 
1.445 and 1.356 DID respectively in 2012. The analysis results showed that azithro-
mycin was leading as of consumption in DID in 2010-2012. Every year, the consump-
tion of this preparation increases. Compared to 2010, in 2012 the azithromycin DID 
consumption index increased for 21.4% and amounted to 0.7931 DID. This means 
that 5.8% of the population of Ukraine takes one course of azithromycin (5 days) 
during the year. Growth of azithromycin consumption is associated with its high 
efficacy. It is accumulated in most tissues and organs, it has the least side effects 
and provides high compliance; it is used in pediatric practice from an early age. 
Azithromycin consumption rate in Russia and Kazakhstan increases every year as 
well. Calculations showed that 2.12% of the population took a course of azithromy-
cin in Russia during 2012; in Kazakhstan, this index equaled 4.59%. ConClusions: 
The analysis showed that, macrolide antibiotics consumption level in Ukraine, 
Kazakhstan and Russia within the study period was comparable.
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Recently licensed quadrivalent influenza vaccines (QIVs) containing a strain from 
each B lineage should address these issues, but their impact still needs to be 
estimated. Our study assesses retrospectively what would have been the public 
health benefit of routinely vaccinating the US population with QIV instead of 
TIV. Methods: We developed a dynamic compartmental model able to account 
for interactions between influenza B lineages (natural or vaccine-induced). The 
model simulates influenza dynamics for the period 2000-2014, to account for the 
long-term impact of infection and vaccination. Age-structured population dynam-
ics, vaccine efficacy (VE) per strain, and weekly ramp-up of vaccination coverage 
are modelled. Sensitivity analyses were performed on VE, duration of immunity, 
levels of vaccine-induced cross-protection between B strains. Results: Assuming 
a cross-protection of 70% of the matched VE, the model predicts that QIV would 
have prevented on average 15% more B-lineages cases. Elderly people (65+yo) and 
young seniors (50-64yo) benefit the most from QIV with 21% and 18% reduction 
of B cases respectively in those age groups. Reducing the cross-protection esti-
mate of the matched VE to 50%, 30%, and 0% improves the relative benefit of QIV 
to 25%, 30%, and 34% fewer B cases in the US. ConClusions: Using a realistic 
retrospective framework, with real-life vaccine mismatch, our analysis shows 
that routine vaccination with QIV has the potential to substantially reduce the 
number of influenza infections, even with relatively conservative estimates of 
TIV induced cross-protection.
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objeCtives: Human Papillomavirus (HPV) is the primum movens both in the eti-
opathogenesis of invasive cervical cancer and in other neoplastic malignant and 
benign lesions. HPV vaccination was implemented in Italy since 2008. The aim of 
this study is to evaluate the burden of HPV-related diseases and the effect of cur-
rent HPV-vaccination strategy in Italy. Methods: A multistate morbidity mortality 
model was developed in order to estimate the infection process on a theoretical 
cohort of Italian women. The conceptual Markov process was adapted considering 
the data available in national and international literature. 7 states (Health, Genital 
Warts, Grade 1 and Grade 2/3 cervical intraepithelial neoplasia, Cervical Cancer, 
Death for Cervical Cancer and death for other cause) and 18 transition probabili-
ties were considered. A 5-years incidence rate class was extrapolated and Rogers 
and Ledent method transformation was used to convert rates into probabilities. 
Vaccination efficacy was carried out by literature modelling review and based to 
the coverage rate of the two anti-HPV vaccines available in Italy. Life expectancy 
(ex), Quality Adjusted Life Years (QALYs), Disability Adjusted Life Years (DALYs) and 
Attributable risk (AR) were estimated for no intervention and vaccination strategies 
scenarios. Results: The preliminary results show that for a theoretical cohort of 
100,000 Italian women the e0 is equal to 84.31 years. With the present HPV vac-
cination strategy the e0 increase to 84.36 (+0.05) years. However, considering the 
HPV-related diseases altogether, the QALYs increase from 83.9 for no intervention 
to 84.1 for Vaccine prevention approach (+0.2QALYs). DALYs decrease of 0.6 thanks 
to Vaccination (2 DALYs for no intervention cohort vs 1.4 DALYs lived for vaccinated 
cohort). AR is equal to 0.08 and 0.29 for population and not vaccinated respec-
tively. ConClusions: The model demonstrates that, if we consider different HPV-
related diseases, Italian HPV vaccination strategy has significantly effect on health 
gains for female population.
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Sun L., Dong H., Wang Y., Shi W., Zhao X., Wu J.
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objeCtives: To evaluate the efficacy and safety of ceftriaxone and levofloxacin 
in treating community-acquired pneumonia and provide references for clinical 
application. Methods: This was a systematic review. Data were collected from 
literature (randomized controlled trails) published from January 2003 to January 
2014 through searching databases both at home and abroad, such as CNKI, 
WanFang Data, VIP, PubMed, Science Direct, Springer, Ovid, Wiley-Blackwell and 
The Cochrane Library (Issue1, 2014). Both qualitative analysis and quantitative 
analysis were conducted. Quantitative analysis (meta-analysis) was performed 
by RevMan 5.2. Results: Nine studies were included, involving 2233 patients. Of 
these, six studies (553 patients) met meta-analysis criteria. The results of meta-
analysis were clinical effective rates (RR= 0.90, 95%CI, P= 0.002), and adverse events 
rates (RR= 0.70, 95%CI, P= 0.22). The result of qualitative description as follows: 
one prospective, randomized study showed success rate were 89% in the ceftri-
axone group and 96% in the levofloxacin group; one multicenter retrospective 
study showed the mortality of the two groups were 3.1% and 2.0%, the length of 
hospital stay (LOS) were 5.5±3.5 days and 4.8±2.9 days respectively, with no sig-
nificant difference found between groups; the other retrospective study showed 
ceftriaxone could shorten LOS since it had a trend toward earlier switch to oral 
therapy. ConClusions: In general, current evidence shows that the efficacy 
for the treatment of community-acquired pneumonia of levofloxacin is superior to 
ceftriaxone, there were no significant difference in the incidence of adverse reaction.
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fIdaxoMICIN TheraPy for PaTIeNTs wITh ClosTrIdIuM dIffICIle 
INfeCTIoN: a sysTeMaTIC lITeraTure revIew aNd MeTa-aNalysIs
Baji P., Gulacsi L., Strbák B., Péntek M., Brodszky V.
Corvinus University of Budapest, Budapest, Hungary
objeCtives: C. difficile is the leading cause of antibiotic associated infectious noso-
comial diarrhoea. A limited number of new pharmaceutical products have been 
developed and registered in past decades for the treatment of C. difficile infection. 
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objeCtives: Seasonal influenza causes substantial public health burden world-
wide. Currently, trivalent vaccines containing two strains of influenza A and one of 
the two circulating influenza B strain lineages (Yamagata and Victoria) are mostly 
used. In recent years, the co-circulation of these two influenza B lineages has cre-
ated some mismatch with the recommended vaccine. The objective is to summa-
rize the epidemiology, burden and seasonality of influenza B in nine European 
countries: Switzerland, Austria, Belgium, Luxembourg, Finland, Greece, Czech 
Republic, Slovakia and Estonia. Methods: Comprehensive review of PubMed and 
Cochrane library as of the year 2003. Additionally, a search in other data sources, 
such as websites of WHO, ECDC and national surveillance for influenza was per-
formed. Results: 10 peer-reviewed articles were included: 10 reported on epi-
demiology, 6 on disease burden and 3 on circulating strains. From grey literature, 
additional data on influenza B circulating lineages and vaccine were provided. 
Incidence data were only available for Finland. No information was found on inci-
dence or prevalence of influenza B for any other country. Articles lacked a defined 
catchment population and only proportions of influenza B among a specified popu-
lation or surveillance samples could be obtained. Though Influenza B-associated 
hospitalization rate among children < 1 year was reported in one article for Finland, 
no additional information was found on influenza B-associated hospitalizations or 
outpatient visits or emergency room for any of the other countries. Information on 
other outcome measures for disease severity was scarce as well. Seasonal variation 
and circulating strains were scarcely presented in peer-reviewed literature; some 
data were found in grey data sources though. ConClusions: While surveillance 
systems have identified the co-circulation of 2 influenza B lineages and vaccine 
mismatch, there is still a low awareness about its burden probably due to the lack 
of appropriately designed studies in the assessed countries.
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PoTeNTIal ePIdeMICs of drugs resIsTaNT BaCTerIa IN PoverTy 
sTrICkeN CouNTrIes lIke PakIsTaN
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objeCtives: Antibiotics are the only promising drugs used to control bacterial 
diseases but their inappropriate use has rendered bacteria resistant. Bacteria have 
been found resistant to all classes of antibiotics including the last line antibiotics 
carbapenems. These multidrug resistant bacteria are a constant threat to human 
health. The aim of this study was to check for pathogenic contaminants in drink-
ing water samples across Pakistan check their drug resistant level too. Methods: 
Drinking water samples were collected from different regions across Pakistan and 
microorganisms present in these samples were identified. Kirby-Bauer disc diffu-
sion tests were used to check the pattern of antibiotic resistance. Interpretation 
was done according to Clinical and Laboratory Standards Institute (CLSI) recom-
mendations. Results: Almost all of the water samples collected were contami-
nated with bacteria or protozoans. All of the contaminated samples had Escherichia 
coli, while many of them had Cryptosporidium spp and Giardia spp. Escherichia 
coli isolates were found resistant to many groups of antibiotics including carbap-
enems (17%). Antibiotics were not helpful against Cryptosporidium and Giardia 
spp. ConClusions: Because of the unhygienic living style and poverty, the threat 
of these resistant bacteria is increasing, and since carbapenems are drugs of the last 
resort such a high prevalence of resistant bacteria in drinking water is an alarming 
threat and holds the potential of future outbreaks.
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dIsaBIlITy-adjusTed lIfe years (dalys) as a CoMPosITe Measure To 
exPress The BurdeN of TICk-BorNe eNCePhalITIs (TBe) IN sloveNIa
Šmit R., Postma M.J.
University of Groningen, Groningen, The Netherlands
objeCtives: TBE is a serious central nervous system disease, which may lead to 
permanent neurological sequelae or even death. TBE is becoming a high burden in 
many parts of Europe, Asian Russia, Siberia, Asian former USSR and Far East. The 
burden is usually expressed by only the incidence or death. DALYs give a composite 
assessment of TBEʼs burden while only the incidence or deaths does not really indi-
cate the real impact on burden. The purpose of the present study is to estimate the 
burdens from the population- and individual perspectives for TBE in Slovenia, meas-
ured in DALYs and evaluate the possibilities of reducing this burden. Methods: 
The burden of TBE in Slovenia is estimated by using the updated DALYs’ method-
ology first introduced by Murray and co-workers in the Global Burden of Disease 
(GBD) project. Adjustment to correct for under-reporting and under-ascertainment 
is applied. Calculations were based on the health outcomes of the natural course of 
TBE. Results: From the population perspective DALYs amount to 3,450 while from 
the individual perspective they amount to 3.1. The neurological sequelae have the 
largest impact on the overall DALYs measurement for TBE. ConClusions: Rising 
awareness and increasing vaccination coverage for TBE is proposed for the whole 
population to reduce the burden and provide health benefits to the population as 
a whole in Slovenia.
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objeCtives: Nowadays populating a decision-making model with input data has 
become a cumbersome process due to the numerous choices of data sources. To 
tackle this issue, regulatory and re-imbursement agencies encourage “evidence 
synthesis for decision making”. To this end meta-analysis methods are gaining 
renewed interest as a means of summarizing results of multiple scientific papers 
objeCtives: To describe long term outcomes of one of the first cohort of HIV 
positive patients started on antiretroviral treatment (ART) in Sub-Saharan 
Africa. Methods: We report 10-years outcomes including mortality, retention, 
CD4-count response, viral suppression (achievement of viral load (VL) < 400 copies/
ml by month-6) and failure (2 consecutive VL> 400 copies/ml or 1 VL> 5000 cop-
ies/ml-as per WHO guidelines), drug substitution from a prospective cohort of 559 
patients initiating ART between April 2004-April 2005 and followed up for 10-years 
in Kampala, Uganda. Results: Of 559 patients, 70% were female, median age (IQR) 
was 38 (33–44) years, median CD4-count (IQR) 98 (21–163) cell/µL, VL (log10) 5.4 
(5.0–5.8) copies/ml. 414 (74%) were started on stavudine+lamivudine+nevirapine, 
145 (26%) on zidovudine+lamivudine+efavirenz. After 10 years 361 (65%) patients 
were still in the study; 123 (22%) had died; 30 (5%) were lost to follow-up; 27 (5%) 
transferred; 18 (3%) withdrew consent. Mortality was high in the first year (80/123, 
65%) and substantially reduced over time. The median gain in CD4-count (IQR) was 
of 477 (199-738) cell/µL and 321 (57.4%) reached 400 cells/µL (lower limit of normal 
CD4-count in Ugandans). 82% (388/473) with available VL at month-6 achieved viral 
suppression (VL< 400 copies/ml), and of those 44 (9.1%) experienced viral failure 
after a median time (IQR) of 45 (17-69) months on ART. 73 (13.1%) switched to second 
line regimen due to ART failure. We observed 184 drug substitutions; before the 
new WHO guidelines release (2009) 52% of these (74/142) were due to toxicity as 
compared to only 17% (7/40) after 2009. ConClusions: High rate of early mortality 
due to advanced disease at presentation resulted in suboptimal retention; however 
good treatment response and first line durability was achieved in patients retained 
on treatment. Rates of drug substitution were high particularly up to 2009 due to 
the use of less tolerated regimes in this period.
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objeCtives: To determine the relationship between utilization of the HIV transi-
tion clinic utilization at the Infectious Diseases Institute (HTC-IDI) and general 
wellbeing of young adults living with HIV/AIDS (YALHA). Methods: This cross 
sectional study was conducted between March and May 2012 at the HTC-IDI in 
Kampala, Uganda. The study recruited 379 YALHA who were between the ages of 
15-24 years. HTC-IDI utilization was categorized into two levels; regular (kept all 
the appointments visits) and irregular (missed one or more appointments visits) 
utilization. The general well-being of YALHA was measured using the 18-item 
general wellbeing schedule (GWS-18). The responses to each item of the GWS-
18 were aggregated and the scores were converted to a 0-100 point scale (100= 
Highest general wellbeing status). Factor analysis was used to systematically group 
the GWS-18 questionnaire. Unpaired t-test, and multivariable logistic regression 
were used to determine the association between utilization and general wellbe-
ing. Results: The mean (SD) age was 22.5±2.0 years with an age range of 15 to 24 
years and the mean (SD) CD4 cell count was 402.3±293.3 with a range of 1-2603/µl, 
231 (60.9%) were currently on ART. Of the 379 YALHA, only 32.4% regularly utilized 
the HTC. The GWS-18 tool was highly acceptable, easily administered and was 
systematically grouped into two factors (anxiety and self-control). The overall scale 
demonstrated good internal consistency with Cronbach’s alpha of 0.82. There was 
no statistically significant association between general wellbeing and utilization of 
the HIV transition clinic. ConClusions: The current study found no significant 
relationship between HTC-IDI utilization and the general well being of YALHA. 
Future studies should use longitudinal designs to ensure long-term follow up of 
the YALHA using disease specific generic tools since well-being has a tendency 
of fluctuating depending on emotional and physical feelings, which may not be 
captured in a cross sectional study.
PIN14
The ePIdeMIologIC BurdeN of hePaTITIs C vIrus INfeCTIoN IN egyPT
Szabo S.M.1, Juarez-Garcia A.2, Levy A.R.1, Donato B.M.K.3
1ICON Epidemiology, Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Mexico City, 
Mexico, 3Bristol-Myers Squibb Company, Wallingford, CT, USA
objeCtives: Chronic infection with hepatitis C virus (HCV) is a major public 
health concern in Egypt. Prevalence data exist, but methods to estimate the epi-
demiologic burden have varied and there has been no systematic approach to 
synthesize these data. The objective of this study is to synthesize published reports 
of prevalence and estimate the total number of HCV cases in Egypt. Methods: A 
systematic search was implemented by two reviewers in the EMBASE, Medline, and 
Cochrane databases, to identify and extract data from population-based studies 
of the epidemiologic burden of HCV in Egypt. Estimates based on laboratory-
confirmed HCV infection, published between January 1, 1995 and May 13, 2014, 
were included. Published data were supplemented with data from the National 
Blood Transfusion Center (NBTC) in Egypt. 2014 population estimates were used 
to project the number of persons infected based on synthesized prevalence esti-
mates. Results: From 630 abstracts, 23 studies were identified. The population-
based Demographic and Health Survey (DHS) estimated the prevalence of active 
infection at 9.8% and overall HCV infection at 14.9%; which is likely an underesti-
mate of e the total population affected since DHS was restricted to people 15 to 55 
years of age. Estimates from blood donors from the NBTC were ~7.5%, supporting 
the low estimate from DHS. Population-based estimates from studies conducted 
in areas of high infectivity were as high as 40 to 50% HCV prevalence. Based on 
a prevalence estimate of 15% (12-18%), approximately 13 million (10-16 million) 
people are infected with HCV in Egypt. ConClusions: Although estimates of the 
prevalence of HCV vary, the wealth of evidence suggests that there is an extensive 
epidemiologic burden in Egypt. With the availability of new therapies, decision-
makers and clinicians need accurate estimate of disease prevalence to assess the 
cost-benefit ratio of new HCV treatments.
